Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME randomised trial

Diabetologia - Clinical and Experimental Diabetes and Metabolism Jul 11, 2018

Verma S, et al. - The effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on cardiovascular events and mortality in participants with type 2 diabetes and a self-reported history of coronary artery bypass graft (CABG) surgery were determined in this post hoc analysis of the EMPA-REG OUTCOME trial. Researchers reported that treatment with empagliflozin was correlated with dramatic reductions in cardiovascular and all-cause mortality, hospitalization for heart failure, and...

Go to Original

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.